Host-Directed Virus-Mimicking Particles Interacting with the ACE2 Receptor Competitively Block Coronavirus SARS-CoV-2 Entry
Source abstract
Abstract
Herein, we fabricate host-directed virus-mimicking particles (VMPs) to block the entry of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) into host cells through competitive inhibition enabled by their interactions with the angiotensin-converting enzyme 2 (ACE2) receptor. A microfluidic platform is developed to fabricate a lipid core of the VMPs with a narrow size distribution and a low level of batch-to-batch variation. The resultant solid lipid nanoparticles are decorated with an average of 231 or 444 Spike S1 RBD protrusions mimicking either the original SARS-CoV-2 or its delta variant, respectively. Compared with that of the nonfunctionalized core, the cell uptake of the functionalized VMPs is enhanced with ACE2-expressing cells due to their strong interactions with the ACE2 receptor. The fabricated VMPs efficiently block the entry of SARS-CoV-2 pseudovirions into host cells and suppress viral infection. Overall, this study provides potential strategies for preventing the spread of SARS-CoV-2 or other coronaviruses employing the ACE2 receptor to enter into host cells.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: SARS-CoV-2 and COVID-19 Research · SARS-CoV-2 detection and testing · Molecular Communication and Nanonetworks
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Helsinki 00014, Finland
Finncure Oy, Lars Sonckin Kaari 14, Espoo 02600, Finland
Department of Biomaterials and Biomedical Technology, University Medical Center Groningen, University of Groningen, Ant. Deusinglaan 1, 9713 AV Groningen, The Netherlands
Funding
Business Finland · ELY Centres project · FinnCure Ltd · Runar B?ckstr?m foundation
References (36)
Show source-provided references
1. 10.1038/s41591-022-02051-310.1038/s41591-022-02051-3 ↗
2. 10.1038/s41580-021-00418-x10.1038/s41580-021-00418-x ↗
3. 10.1038/s41423-020-0400-410.1038/s41423-020-0400-4 ↗
4. 10.1002/rmv.220710.1002/rmv.2207 ↗
5. 10.1021/acsnano.0c0683610.1021/acsnano.0c06836 ↗
6. 10.1038/nrmicro282010.1038/nrmicro2820 ↗
7. 10.3390/cells1002030010.3390/cells10020300 ↗
8. 10.1126/scisignal.129re810.1126/scisignal.129re8 ↗
9. 10.1038/nrmicro303610.1038/nrmicro3036 ↗
10. 10.1073/pnas.211989311910.1073/pnas.2119893119 ↗
11. 10.1016/j.cell.2020.02.05210.1016/j.cell.2020.02.052 ↗
12. 10.1038/s41586-020-2286-910.1038/s41586-020-2286-9 ↗
13. 10.1038/nrd.2017.16210.1038/nrd.2017.162 ↗
14. 10.1016/j.antiviral.2019.04.00610.1016/j.antiviral.2019.04.006 ↗
15. 10.1038/s41467-022-34111-010.1038/s41467-022-34111-0 ↗
16. 10.1038/s41588-023-01307-z10.1038/s41588-023-01307-z ↗
17. 10.1128/CMR.00168-1910.1128/CMR.00168-19 ↗
18. 10.1016/j.bj.2020.04.00710.1016/j.bj.2020.04.007 ↗
19. 10.1038/nature1311810.1038/nature13118 ↗
20. 10.1038/nature0505810.1038/nature05058 ↗
21. 10.1002/adma.20221125410.1002/adma.202211254 ↗
22. 10.1021/acs.langmuir.5b0279710.1021/acs.langmuir.5b02797 ↗
23. 10.1021/la035864n10.1021/la035864n ↗
24. Das P. · 2022 · 9510.1016/B978-0-323-91077-4.00006-5 ↗
25. 10.1038/s41467-020-20654-710.1038/s41467-020-20654-7 ↗
26. 10.3390/vaccines904039510.3390/vaccines9040395 ↗
27. 10.3389/fnins.2023.111784510.3389/fnins.2023.1117845 ↗
28. 10.3390/v1407136910.3390/v14071369 ↗
29. 10.1128/JVI.79.15.9470-9479.200510.1128/JVI.79.15.9470-9479.2005 ↗
30. 10.3390/cells1104062710.3390/cells11040627 ↗
31. 10.1038/s41433-020-0939-410.1038/s41433-020-0939-4 ↗
32. 10.1016/j.ejps.2020.10566810.1016/j.ejps.2020.105668 ↗
33. 10.1038/s41467-020-16048-410.1038/s41467-020-16048-4 ↗
34. 10.1038/s41596-020-0394-510.1038/s41596-020-0394-5 ↗
35. 10.1002/jmv.2840610.1002/jmv.28406 ↗
36. 10.1016/j.str.2022.07.00510.1016/j.str.2022.07.005 ↗